Quantcast

Latest Adaptive Biotechnologies Corporation Stories

2014-07-08 12:28:58

SEATTLE, July 8, 2014 /PRNewswire/ -- Adaptive Biotechnologies, a clinical stage diagnostics company that leverages Next Generation Sequencing (NGS) to profile the adaptive immune system, is pleased to announce the appointment of Sean Nolan as Chief Technology Officer and the newest member of the Company's expanding Executive Leadership Team. Mr. Nolan's hire, the second management hire this month, represents Adaptive's continued commitment to incorporating state-of-the-art data...

2014-06-27 12:26:33

Study published in Clinical Cancer Research and co-led by Adaptive Biotechnologies and the University of Washington demonstrates clinical utility of Next Generation Immune Profiling SEATTLE, June 27, 2014 /PRNewswire/ -- Adaptive Biotechnologies today announced results demonstrating enhanced accuracy and sensitivity of clonoSEQ in identifying risk of relapse in patients with B-cell Acute Lymphoblastic Leukemia (B-ALL), a childhood leukemia, compared to flow cytometry, the current...

2014-06-19 16:26:33

SEATTLE, June 19, 2014 /PRNewswire/ -- Adaptive Biotechnologies, a clinical stage diagnostics company that leverages Next Generation Sequencing (NGS) to profile the adaptive immune system, is pleased to announce the appointment of Dean Schorno, CPA, as Chief Financial Officer and the newest member of the Company's expanding Executive Leadership Team. http://photos.prnewswire.com/prnvar/20120103/SF28632LOGO "The addition of a true pioneer in oncology diagnostics is highly...

2014-05-27 12:32:22

SEATTLE, May 27, 2014 /PRNewswire/ -- Adaptive Biotechnologies, the pioneer of Next Generation Sequencing of the adaptive immune system, and its collaborators will present data supporting the clinical application of immunosequencing in diagnosing and monitoring T cell lymphomas at the 2014 Annual Meeting of the American Society of Clinical Oncology. Data will also be presented demonstrating how immunosequencing can be used to elucidate the activity of immunotherapeutic combination...

2014-04-07 12:33:36

Investment fuels expansion of industry-leading immunosequencing research platform and diagnostic products for the treatment of cancer, autoimmune disorders, and infectious diseases SEATTLE, April 7, 2014 /PRNewswire/ -- Adaptive Biotechnologies announced today the completion of the Company's Series C financing round and the completion of a newly created Series D round with a $105 million investment from Viking Global Investors. This investment will enable the Company to expand...

2014-01-13 12:27:53

SEATTLE, Jan. 13, 2014 /PRNewswire/ -- Adaptive Biotechnologies announced today a biomarker discovery agreement facilitated by the Johnson & Johnson Innovation Center in California. Under the agreement, Adaptive will use its patented immune profiling assay, immunoSEQ(TM), to enable an in-depth characterization of the immune response to diseases being studied and select immunology and oncology drugs being developed by Janssen Research & Development, LLC (Janssen). The...

2014-01-08 12:29:43

SEATTLE, Jan. 8, 2014 /PRNewswire/ -- Adaptive Biotechnologies (www.adaptivebiotech.com) announced today that Chad Robins, Founder and Chief Executive Officer, is scheduled to present a company overview at the 32(nd) Annual J.P. Morgan Healthcare Conference in San Francisco on Wednesday, January 15(th), 2014 at 2:00pm PST. (Logo: http://photos.prnewswire.com/prnh/20120103/SF28632LOGO) About AdaptiveAdaptive Biotechnologies Corporation ("Adaptive" or the "Company") is a pioneer in...


Word of the Day
pungle
  • To take pains; labor assiduously with little progress.
This word comes from the Spanish 'pongale,' put it.
Related